KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Inventory (2016 - 2024)

Historic Inventory for Nektar Therapeutics (NKTR) over the last 15 years, with Q2 2024 value amounting to $14.5 million.

  • Nektar Therapeutics' Inventory fell 3008.36% to $14.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $14.5 million, marking a year-over-year decrease of 3008.36%. This contributed to the annual value of $16.1 million for FY2023, which is 1614.94% down from last year.
  • According to the latest figures from Q2 2024, Nektar Therapeutics' Inventory is $14.5 million, which was down 3008.36% from $16.2 million recorded in Q1 2024.
  • In the past 5 years, Nektar Therapeutics' Inventory ranged from a high of $20.7 million in Q2 2023 and a low of $12.6 million during Q2 2020
  • In the last 5 years, Nektar Therapeutics' Inventory had a median value of $15.6 million in 2021 and averaged $16.2 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Inventory skyrocketed by 3157.55% in 2023, and later tumbled by 3008.36% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Inventory (Quarter) stood at $15.3 million in 2020, then grew by 3.33% to $15.8 million in 2021, then increased by 21.52% to $19.2 million in 2022, then dropped by 16.15% to $16.1 million in 2023, then fell by 10.16% to $14.5 million in 2024.
  • Its last three reported values are $14.5 million in Q2 2024, $16.2 million for Q1 2024, and $16.1 million during Q4 2023.